大剂量阿糖胞苷用于急性髓细胞白血病完全缓解后巩固强化治疗的疗效及不良反应

High dose Cytarabine Has been Used in the Treatment of Acute Myeloid Leukemia after Complete Remission

目的分析大剂量阿糖胞苷(high dose cytarabine,Ara-c)用于急性髓细胞白血病(acute myeloid leukemia,AML)完全缓解后巩固强化治疗的疗效及不良反应。方法本文收治对象为完全缓解后AML患者,总例数为200例,收取时间在2018年5月10日至2019年2月10日,总例数采取抽签分组方式分为两组,观察组100例(实施大剂量Ara-c)、对照组100例(实施标准巩固强化治疗),将两组的早期复发率、不良反应发生率、3年生存率进行对比。结果观察组早期复发率15.00%显著低于对照组患者早期复发率31.00%(P<0.05);观察组不良反应发生率指标4.00%低于对照组患者(P <0.05);观察组3年生存率59.00%显著高于对照组的3年生存率(P<0.05)。结论大剂量Ara-c用于AML完全缓解后患者中,取得一定效果,能显著降低患者复发率,减少不良反应。

Objective To analyze the efficacy and adverse reactions of high-dose cytarabine in the treatment of acute myeloid leukemia after complete remission. Method In this paper, the treated object for after complete remission of acute myelogenous leukemia patients, total of 200 cases, charging time on May 10, 2018-February 10, 2019, total number of cases to draw grouping is divided into two groups, observation group 100 cases(the implementation of high-dose cytarabine), the control group, 100 cases(the implementation of standard consolidated therapy), the two groups of early recurrence rate, incidence of adverse reactions, 3 year survival rate were compared. Results The early recurrence rate of the observation group was significantly lower than 31.00% of the control group(P<0.05). The incidence of adverse reactions in the observation group was 4.00% lower than that in the control group(P<0.05). The 3-year survival rate of the observation group was 59.00% significantly higher than that of the control group(P<0.05). Conclusion High-dose cytarabine can significantly reduce the recurrence rate and adverse reactions in patients with acute myeloid leukemia after complete remission.